StockData
ImageneBio, Inc. logo

ImageneBio, Inc. (IMA) stock

IMANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 6/30
$3.81−0.09 (-2.31%)

Close on Nov 18, 2026Market cap $43.25MP/E –Yield –

ImageneBio free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

ImageneBio's free cash flow for the twelve months ending Dec 31, 2023 was -$80.16M. For fiscal 2023 it was -$80.16M.

Annual free cash flow

PeriodPeriod endValueChange
FY2023Dec 31, 2023-$80.16M–
FY2022Dec 31, 2022-$75.54M–
FY2021Dec 31, 2021-$62.01M–
FY2020Dec 31, 2020-$38.59M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2023Dec 31, 2023-$22.08M–
Q3 FY2023Sep 30, 2023-$20.00M–
Q2 FY2023Jun 30, 2023-$18.14M–
Q1 FY2023Mar 31, 2023-$19.94M–
Q4 FY2022Dec 31, 2022-$17.89M–
Q3 FY2022Sep 30, 2022-$18.35M–
Q2 FY2022Jun 30, 2022-$19.49M–
Q1 FY2022Mar 31, 2022-$19.82M–
Q4 FY2021Dec 31, 2021-$13.92M–
Q3 FY2021Sep 30, 2021-$18.17M–
Q2 FY2021Jun 30, 2021-$15.91M–
Q1 FY2021Mar 31, 2021-$14.01M–
Q4 FY2020Dec 31, 2020-$13.22M–
Q3 FY2020Sep 30, 2020-$7.67M–
Q2 FY2020Jun 30, 2020-$7.71M–
Q1 FY2020Mar 31, 2020-$9.99M–

More ImageneBio figures

See a number that looks wrong?